ArticleAmerican journal of clinical and experimental urology2026
Testicular endocrine function recovers following Fournier's gangrene.
Article in American journal of clinical and experimental urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBetween 5.6-21% of Fournier's Gangrene (FG) patients undergo orchiectomy, despite testicular viability. Arguments for this practice center around the presumed lack of functional recovery following critical illness as well as improved ease of wound closure. We aimed to study the effects of FG on the hypothalamic-pituitary-gonadal (HPG) axis and characterize hormonal recovery patterns.
methodsWe retrospectively studied male FG patients at a quaternary center from July 2023-September 2024. Total testosterone (TT), free testosterone (FT), luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), and estradiol (E2) at admission, discharge, and follow-up (1-9 months) were examined. Two-sided Wilcoxon signed-rank tests were used to compare paired hormone levels across time points. A validation analysis using two-sided Mann-Whitney U tests was performed to compare hormone distributions between patients with complete vs. incomplete data at all three time points.
resultsOf 31 FG patients, 20 had hormone measurements at multiple time points; 12 had complete data at all time points. All patients presented with castrate to near-castrate levels of TT. TT and FT increased significantly throughout recovery (both P ≤ 0.011). E2 decreased significantly from admission to discharge and from admission to follow-up (P = 0.014 and P = 0.008, respectively). All reconstruction types showed similar recovery patterns.
conclusionsFG transiently suppresses testicular hormone production to castrate levels via the HPG axis. However, the HPG axis has the capacity to recover to physiologic ranges, with testicular steroidogenesis following suit. Without clear evidence of testicular necrosis, efforts should prioritize testicular preservation during debridement and reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.